Patent · US Active

RNAi modulation of Aha and therapeutic uses thereof

US7812150B2 · kind B2 · utility

0Cited by

14References

14Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Rainer Constien · Kulmbach, DE
Birgit Bramlage · Ebikon, CH
Pamela Tan · Kulmbach, DE
Hans-Peter Vornlocher · Bayreuth, DE
William Balch · San Diego, US

Key dates

Filing date	May 18, 2007
Grant date	Oct 12, 2010
Priority date	—
Expiry date	Nov 13, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.